21 completed, 6 terminated, 3 active not recruiting, 1 enrolling by invitation. 23 Phase 1, 12 Phase 2, 2 Not applicable, 1 Phase 4.
Follow Interleukin-12: new trials by email Literature Review of Interleukin-12 trials Research Report on Interleukin-12
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| INSIGHT-IBD Pragmatic Study Mirikizumab, Anti-TNF agents, anti-integrin antibodies - Ulcerative Colitis (UC), Crohn Disease (CD) | Phase 4 | Enrolling by invitation | Specialty Networks Research. | 400 | 2026-08-12 | 2026-10-29 |
| Host Dysregulation-Driven Sepsis Prediction Model Tumor Necrosis Factor, Interleukin-1β, Interleukin-12 - Sepsis | Completed | Second Affiliated Hospital of Wenzhou Medical University | 1000 | 2024-09-01 | 2024-10-31 | |
| Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients. Dendritic Cell/Tumor Fusion Vaccine, Interleukin-12, Temozolomide - Glioblastoma, Glioma | Phase 1 / Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 10 | 2020-12-01 | 2020-06-09 |
| Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 36 | 2018-05-30 | 2026-11-12 |
| A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML) IL-12 - Acute Myeloid Leukemia | Phase 1 | Active not recruiting | University Health Network, Toronto | 9 | 2015-09-01 | 2025-12-01 |
| Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults PENNVAX®-GP HIV-1 DNA vaccine, Interleukin-12 (IL-12) DNA adjuvant, Placebo - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 94 | 2015-08-01 | 2021-10-15 |
| hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse INO-1400, INO-9012, INO-1401 - Breast Cancer, Lung Cancer | Phase 1 | Completed | Inovio Pharmaceuticals | 93 | 2014-12-01 | 2018-11-19 |
| Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery Cetuximab, Edodekin alfa, Laboratory Biomarker Analysis - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 23 | 2011-10-26 | 2026-07-29 |
| Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer Fludarabine, Cyclophosphamide, IL-12 & Anti-NY ESO1 TCR PBL - Metastatic Cancer, Metastatic Melanoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 2 | 2011-10-06 | 2019-01-08 |
| Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults Profectus HIV MAG pDNA vaccine, IL-12, Placebo - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 62 | 2011-03-01 | 2021-11-01 |
| Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12 Dendritic Cell/Tumor Fusion Vaccine, Interleukin-12 - Breast Cancer | Phase 1 / Phase 2 | Terminated | Beth Israel Deaconess Medical Center | 8 | 2009-12-01 | 2017-11-14 |
| Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults PennVax B, IL-12, IL-15 - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 120 | 2007-10-01 | 2021-10-14 |
| Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma recombinant interleukin-12, aldesleukin - Recurrent Neuroblastoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 40 | 2002-12-01 | 2013-04-09 |
| Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides aldesleukin, recombinant interleukin-12, laboratory biomarker analysis - Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 46 | 2002-09-01 | 2013-01-16 |
| Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy PSA prostate cancer vaccine, recombinant interleukin-12 - Prostate Cancer | Phase 2 | Completed | University of Chicago | 13 | 2001-11-01 | 2014-03-07 |
| Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors trastuzumab, paclitaxel, recombinant interleukin-12 - Male Breast Cancer, Recurrent Breast Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 18 | 2001-11-01 | 2013-06-04 |
| Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma rituximab, recombinant interleukin-12, laboratory biomarker analysis - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 99 | 2001-10-01 | 2013-08-26 |
| Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma recombinant interleukin-12, recombinant interferon alfa, laboratory biomarker analysis - Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 60 | 2001-10-01 | 2013-06-05 |
| Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer recombinant interleukin-12 - Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 30 | 2001-07-01 | 2013-01-23 |
| Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors recombinant interleukin-12, aldesleukin, laboratory biomarker analysis - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | National Cancer Institute (NCI) | 25 | 2000-03-01 | 2013-02-01 |
Showing 20 of 32. Sign in to see all of them.
HIV Infections (8) · Breast Neoplasms (4) · Acquired Immunodeficiency Syndrome (3) · Carcinoma, Ovarian Epithelial (3) · Squamous Cell Carcinoma of Head and Neck (3) · Stomach Neoplasms (3) · Breast Neoplasms, Male (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Cryptosporidiosis (2) · Endometrial Neoplasms (2) · Esophageal Neoplasms (2) · Head and Neck Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2)
National Cancer Institute (NCI) (13) · National Institute of Allergy and Infectious Diseases (NIAID) (11) · Beth Israel Deaconess Medical Center (1) · Dana-Farber Cancer Institute (1) · Inovio Pharmaceuticals (1) · Second Affiliated Hospital of Wenzhou Medical University (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Specialty Networks Research. (1) · University Health Network, Toronto (1) · University of Chicago (1)
United States (28) · China (2) · Canada (1)
William Carson (3) · A. Clinton White (1) · A. Dimitrios Colevas, MD (1) · Alain Rook (1) · Anas Younes (1) · Anthony Shields, MD (1) · Arthur White (1) · Ashish Chintakuntlawar, MBBS, PhD (1) · Autumn McRee, MD (1) · Beverly Sha (1) · Casey Chapman, MD (1) · David Avigan, MD (1) · David Ho (1) · Diwakar Davar (1) · Hassan Sibai, M.D. (1)
PMID 25820067, PMID 26761518, PMID 32437332
U01CA076576 (3), N01CM17003 (2), P30CA006516 (2), N01CM00070 (1), P01CA081403 (1), P30CA016058 (1), R01AI041735 (1), R01CA089442 (1), U01CA062490 (1), U10CA025224 (1), U10CA031946 (1), UM1CA186690 (1), UM1CA186712 (1)